Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized double-blind placebo-controlled single- and multiple-ascending-dose study of GRC 10693 in healthy male volunteers
NL-OMON33904Phase 1Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Neuralgia, postherpetic neuralgia (PHN) and diabetic neuropathy comparing GRC 10693 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Aug 2008; status: active, not recruiting.
02
Drugs
tedalinab
03
Conditions
Neuralgiapostherpetic neuralgia (PHN)diabetic neuropathy
Beyond the preview
Go deeper on NL-OMON33904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33904.